Sickle Cell Society’s response to Crizanlizumab (Adakveo), on an interim basis for use by NHS Scotland.
Sickle Cell Society’s response to the Scottish Medicines Consortium SMC Committee’s decision to accept Crizanlizumab (Adakveo), on an interim basis for use by NHS Scotland:
“Sickle Cell Society’s CEO John James OBE said, “People living with sickle cell disorder and dealing with the recurrent pain episodes, find that every aspect of their daily life is disrupted. Sickle cell disorder has a significant impact on the quality of life of people living with this condition.
We welcome the decision of the Scottish Medicines Consortium and are very pleased that the Sickle Cell Society played its part in enabling access for this new treatment for people living with sickle cell disorder in Scotland.”